Literature DB >> 2539728

Turnover of adenosine in plasma of human and dog blood.

G H Möser1, J Schrader, A Deussen.   

Abstract

To determine half-life and turnover of plasma adenosine, heparinized blood from healthy volunteers was incubated with radiolabeled adenosine in the physiological concentration range of 0.1-1 microM. Plasma levels of adenosine in vitro were 82 +/- 14 nM and were similar to those determined immediately after blood collection with a "stopping solution." Dipyridamole (83 microM) and erythro-9(2-hydroxynon-3yl)-adenine (EHNA) (8 microM) did not measurably alter basal adenosine levels but completely blocked the uptake of added adenosine. Inhibition of ecto-5'-nucleotidase with 100 microM alpha, beta-methyleneadenosine 5'-diphosphate (AOPCP) reduced plasma adenosine to 22 +/- 6 nM. For the determination of adenosine turnover, the decrease in specific radioactivity of added [3H]adenosine was measured using a dipyridamole-containing stopping solution. Without altering basal adenosine levels, the half-life was estimated to be 0.6 s. Similar experiments were carried out with washed erythrocytes or in the presence of AOPCP, yielding half-lives of 0.7 and 0.9 s, respectively. When the initial adenosine concentration was 1 microM, its specific activity decreased by only 11% within 5 s, whereas total plasma adenosine exponentially decreased with a half-life of 1.5 s. Venous plasma concentrations were measured after relief of a 3-min forearm ischemia. Changes in plasma adenosine did not correlate well with changes in blood flow but were augmented in the presence of dipyridamole.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539728     DOI: 10.1152/ajpcell.1989.256.4.C799

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  121 in total

1.  The effect of ABT-702, a novel adenosine kinase inhibitor, on the responses of spinal neurones following carrageenan inflammation and peripheral nerve injury.

Authors:  R Suzuki; L C Stanfa; E A Kowaluk; M Williams; M F Jarvis; A H Dickenson
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

2.  Imaging of adenosine bolus transit following intravenous administration: insights into antiarrhythmic efficacy.

Authors:  G A Ng; W Martin; A C Rankin
Journal:  Heart       Date:  1999-08       Impact factor: 5.994

Review 3.  The impact of caffeine on vasodilator stress perfusion studies.

Authors:  Andre C Lapeyre; Tauqir Y Goraya; Donald L Johnston; Raymond J Gibbons
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

Review 4.  Adenosine 2A receptors in acute kidney injury.

Authors:  I S Vincent; M D Okusa
Journal:  Acta Physiol (Oxf)       Date:  2015-05-19       Impact factor: 6.311

5.  Adenosine and cardiac arrhythmias.

Authors:  C J Garratt; A D Malcolm; A J Camm
Journal:  BMJ       Date:  1992-07-04

6.  Going with the flow: methotrexate, adenosine, and blood flow.

Authors:  B N Cronstein
Journal:  Ann Rheum Dis       Date:  2006-04       Impact factor: 19.103

7.  Adenosine's usefulness in vascular surgery.

Authors:  Maurice Lippmann; Clinton Kakazu; Tony D Fang; Harold Bui; Carlos Donayre; Rodney A White
Journal:  Tex Heart Inst J       Date:  2007

8.  Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells.

Authors:  Yuliia Kaljas; Chengqian Liu; Maksym Skaldin; Chengxiang Wu; Qing Zhou; Yuanan Lu; Ivona Aksentijevich; Andrey V Zavialov
Journal:  Cell Mol Life Sci       Date:  2016-09-23       Impact factor: 9.261

9.  Adenosine myocardial perfusion single photon emission computed tomographic stress testing 24-72 h after uncomplicated myocardial infarction.

Authors:  Jan Kulhanek; Vincent L Sorrell; Reza E Ershadi; Brian R Cabarrus; Douglas B Short; Assad Movahed
Journal:  Int J Cardiovasc Imaging       Date:  2002-08       Impact factor: 2.357

10.  Noninvasive identification of left main and three-vessel coronary artery disease by thallium-201 single photon emission computed tomography during adenosine infusion.

Authors:  Y Takeishi; J Chiba; S Abe; A Komatani; K Takahashi; H Tomoike
Journal:  Ann Nucl Med       Date:  1994-02       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.